Kendall Capital Management Has $2.54 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kendall Capital Management trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,417 shares of the biopharmaceutical company’s stock after selling 70 shares during the period. Regeneron Pharmaceuticals accounts for approximately 0.8% of Kendall Capital Management’s holdings, making the stock its 29th largest holding. Kendall Capital Management’s holdings in Regeneron Pharmaceuticals were worth $2,540,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Gilbert & Cook Inc. increased its stake in shares of Regeneron Pharmaceuticals by 8.3% in the 4th quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock valued at $1,675,000 after buying an additional 146 shares during the period. TrinityPoint Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.8% in the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 12 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $749,000. D.A. Davidson & CO. increased its stake in shares of Regeneron Pharmaceuticals by 17.0% in the 4th quarter. D.A. Davidson & CO. now owns 709 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 103 shares during the period. Finally, Corient Private Wealth LLC boosted its position in shares of Regeneron Pharmaceuticals by 8.2% in the 4th quarter. Corient Private Wealth LLC now owns 33,561 shares of the biopharmaceutical company’s stock worth $29,476,000 after purchasing an additional 2,537 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $1,138.81 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The stock has a market capitalization of $125.48 billion, a PE ratio of 33.64, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The company’s 50-day moving average is $1,129.45 and its 200-day moving average is $1,029.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the firm earned $8.79 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is owned by corporate insiders.

Analyst Ratings Changes

REGN has been the topic of several recent research reports. Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,111.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.